Articles

ELNs and first-to-file

Electronic lab notebooks are no longer just replacing paper, but enabling collaboration around the globe with IP protection
Written byLloyd Dunlap
| 3 min read

WALTHAM, Mass.—Introduced about 10 years ago, electronic labnotebooks (ELNs) may be the only electronic platforms that have emerged asstrategic players across the market. That's the opinion of Michael Stapleton,general manager of informatics at PerkinElmer, who estimates the market penetrationis still only 30 to 40 percent, leaving massive growth opportunities forcompanies that are the survivors of the latest round of mergers andacquisition, including Sapio Sciences, Agilent, Rescentris, Accelrys and IDBS.

The promised benefits? Ken Rapp, managing director foranalytical, development, quality and manufacturing at Accelrys, explains:"Electronic lab notebooks go far beyond simply replacing paper notebooks. Theysupport process efficiency from start to finish—turning information into aknowledge base that combines the thoughts and intellectual property (IP) frommultiple different sources including research, business and legal teams.

To continue reading this article, subscribe for FREE toDrug Discovery News Logo

Subscribe today to keep up to date with the latest advancements and discoveries in drug development achieved by scientists in pharma, biotech, non-profit, academic, clinical, and government labs.

Add Drug Discovery News as a preferred source on Google

Add Drug Discovery News as a preferred Google source to see more of our trusted coverage.

About the Author

Here are some related topics that may interest you:

Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

3D illustration of a single cell surrounded by small molecular particles in a red biological environment.
Measuring mRNA and protein together at single cell resolution can uncover tumor-specific signaling activity and immune features.
Illustration of an antibody intertwined with a DNA double helix.
Discover how CRISPR and single-cell RNA sequencing can connect disease-associated variants to regulatory elements, genes, and pathways.
Digital illustration of the human digestive system highlighting the liver, stomach, and intestines.
Explore how human gut-liver models can improve the translation of preclinical findings into clinical pharmacokinetic predictions.